GlassScriptPhysician profile
Itha H Harewood
NPI 1124092952
$19,736.16
in general payments reported to CMS, 2019-2025
18 companies · $1,782 in 2025
The $1,782 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,589 · 2020: $1,379 · 2021: $2,835 · 2022: $2,441 · 2023: $4,379 · 2024: $2,331 · 2025: $1,782.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,493.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,492.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $6,276.97 | 2019-2025 | Dovato, Apretude, Cabenuva |
| Gilead Sciences, INC. | $4,311.17 | 2019-2025 | Epclusa, Descovy, Biktarvy |
| Novo Nordisk INC | $2,797.65 | 2019-2025 | Wegovy, Ozempic, Saxenda |
| Janssen Products, LP | $2,093.10 | 2019-2023 | Symtuza |
| Janssen Biotech, INC. | $1,741.95 | 2019-2023 | Symtuza |
| Theratechnologies INC. | $572.98 | 2019-2025 | Trogarzo, Egrifta |
| Amarin Pharma, INC. | $496.91 | 2019 | |
| Merck Sharp & Dohme LLC | $330.01 | 2019-2023 | Pifeltro |
| Lilly USA, LLC | $243.68 | 2024 | Mounjaro |
| Abbvie INC. | $195.82 | 2019-2023 | |
| Janssen Scientific Affairs, LLC | $127.96 | 2023 | Symtuza |
| Astrazeneca Pharmaceuticals LP | $124.92 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $118.97 | 2023 | |
| Paratek Pharmaceuticals, INC. | $117.65 | 2025 | Nuzyra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.82 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $69.70 | 2025 | Nellcor |
| Dynavax Technologies Corporation | $23.15 | 2022 | |
| Novartis Pharmaceuticals Corporation | $22.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Itha Harewood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.